Gasporox (GPX) Q1 2025 earnings summary

Executive summary

• Net sales for Q1 2025 were 3,970 KSEK, down from 8,655 KSEK year-over-year, with a negative operating result of -4,119 KSEK compared to 225 KSEK last year.

• Positive cash flow of 11,120 KSEK, mainly due to convertible loan financing, with cash and cash equivalents at 17,933 KSEK at quarter-end.

• Strategic investments in new technology platforms and product development, including expansion in pharmaceutical vial inspection and the SpectraPore™ project for tablet inspection.

• The company continues to focus on innovation, market expansion, and strengthening its position in quality control for pharmaceutical, food, and beverage packaging.

Financial highlights

• Net sales decreased to 3,970 KSEK from 8,655 KSEK year-over-year; operating result fell to -4,119 KSEK from 225 KSEK.

• EBITDA for Q1 2025 was -2,583 KSEK, down from 1,406 KSEK in Q1 2024.

• Cash flow improved to 11,120 KSEK from -226 KSEK, driven by financing activities.

• Cash and cash equivalents at quarter-end were 17,933 KSEK, up from 10,395 KSEK year-over-year.

• Equity at quarter-end was 22,046 KSEK, with a solid equity ratio of 42%.

Outlook and guidance

• Strong order intake and ongoing deliveries expected to support future quarters.

• Strategic focus on expanding product offerings and entering new market segments, especially in pharmaceuticals and food.

• Market launch of SpectraPore™ for tablet inspection targeted for 2026/2027.